Clinical trial
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
NCT00004132 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004132 |
|---|---|
| Title | Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Patients With Hematologic Malignancies Undergoing Total Body Irradiation (TBI) and High-Dose Chemotherapy With Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy |
| Start date | Jan 1, 2000 |
| Completion | May 1, 2004 |
| First posted | May 20, 2004 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: